Please use this identifier to cite or link to this item: https://doi.org/10.3390/ijms20020257
Title: Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer?s disease (AD): A systematic review and meta-analysis
Authors: Ng, T.K.S
Ho, C.S.H
Tam, W.W.S 
Kua, E.H 
Ho, R.C.-M 
Keywords: brain derived neurotrophic factor
BDNF protein, human
biological marker
brain derived neurotrophic factor
Alzheimer disease
cognitive defect
dementia
disease severity
enzyme linked immunosorbent assay
genetic heterogeneity
human
meta analysis
Mini Mental State Examination
motor dysfunction
neuroprotection
neuropsychiatric inventory
Review
systematic review
Alzheimer disease
animal
blood
case control study
complication
cross-sectional study
disease exacerbation
psychology
publishing
Alzheimer Disease
Animals
Biomarkers
Brain-Derived Neurotrophic Factor
Case-Control Studies
Cognitive Dysfunction
Cross-Sectional Studies
Disease Progression
Humans
Publication Bias
Issue Date: 2019
Citation: Ng, T.K.S, Ho, C.S.H, Tam, W.W.S, Kua, E.H, Ho, R.C.-M (2019). Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer?s disease (AD): A systematic review and meta-analysis. International Journal of Molecular Sciences 20 (2) : 257. ScholarBank@NUS Repository. https://doi.org/10.3390/ijms20020257
Abstract: Findings from previous studies reporting the levels of serum brain-derived neurotrophic factor (BDNF) in patients with Alzheimer’s disease (AD) and individuals with mild cognitive impairment (MCI) have been conflicting. Hence, we performed a meta-analysis to examine the aggregate levels of serum BDNF in patients with AD and individuals with MCI, in comparison with healthy controls. Fifteen studies were included for the comparison between AD and healthy control (HC) (n = 2067). Serum BDNF levels were significantly lower in patients with AD (SMD: −0.282; 95% confidence interval [CI]: −0.535 to −0.028; significant heterogeneity: I 2 = 83.962). Meta-regression identified age (p < 0.001) and MMSE scores (p < 0.001) to be the significant moderators that could explain the heterogeneity in findings in these studies. Additionally, there were no significant differences in serum BDNF levels between patients with AD and MCI (eight studies, n = 906) and between MCI and HC (nine studies, n = 5090). In all, patients with AD, but not MCI, have significantly lower serum BDNF levels compared to healthy controls. This meta-analysis confirmed the direction of change in serum BDNF levels in dementia. This finding suggests that a significant change in peripheral BDNF levels can only be detected at the late stage of the dementia spectrum. Molecular mechanisms, implications on interventional trials, and future directions for studies examining BDNF in dementia were discussed. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
Source Title: International Journal of Molecular Sciences
URI: https://scholarbank.nus.edu.sg/handle/10635/176188
ISSN: 1661-6596
DOI: 10.3390/ijms20020257
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_ijms20020257.pdf1.04 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

45
checked on Apr 4, 2021

Page view(s)

69
checked on Apr 9, 2021

Download(s)

1
checked on Apr 9, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.